Description
TORLISTM {Torsemide}- 5mg/10mg/ 20mg/ 40mg/ 100mg
MODE OF ACTION:
TORLISTM is part of the loop diuretics and thus, it acts by reducing the oxygen demand in the medullary thick ascending loop of Henle by inhibiting the Na+/K+/Cl- pump on the luminal cell membrane surface. This action is obtained by the binding of TORLISTM to a chloride ion-binding site of the transport molecule. TORLISTM is known to have an effect in the renin-angiotensin-aldosterone system by inhibiting the downstream cascade after the activation of angiotensin II. This inhibition will produce a secondary effect marked by the reduction of the expression of
aldosterone synthase, TGF-B1 and thromboxane A2 and a reduction on the aldosterone receptor binding
1. Edema
2. Hypertension
Edema Associated with Renal Disease20 mg once a day
5 mg orally once a day; if diuresis remains inadequate after 4 to 6 weeks, titrate up to
10 mg orally once a day
Symptomatic Hypotension: Advise patients receiving TORLISTM that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing
physician. The patients should be told that if syncope occurs, TORLISTM should be discontinued until the physician has been consulted. All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible
This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.
